Faculty of Medicine, Institute of Cell Biology (Cancer Research), University of Duisburg-Essen, Virchowstr. 177, 45122, Essen, Germany.
Computational Biology Group, Precision Nutrition and Cancer Research Program, IMDEA Food Institute, 28049, Madrid, Spain.
Clin Epigenetics. 2022 Nov 14;14(1):148. doi: 10.1186/s13148-022-01362-z.
The molecular pathogenesis of T-cell large granular lymphocytic leukemia (T-LGLL), a mature T-cell leukemia arising commonly from T-cell receptor αβ-positive CD8 memory cytotoxic T cells, is only partly understood. The role of deregulated methylation in T-LGLL is not well known. We analyzed the epigenetic profile of T-LGLL cells of 11 patients compared to their normal counterparts by array-based DNA methylation profiling. For identification of molecular events driving the pathogenesis of T-LGLL, we compared the differentially methylated loci between the T-LGLL cases and normal T cells with chromatin segmentation data of benign T cells from the BLUEPRINT project. Moreover, we analyzed gene expression data of T-LGLL and benign T cells and validated the results by pyrosequencing in an extended cohort of 17 patients, including five patients with sequential samples.
We identified dysregulation of DNA methylation associated with altered gene expression in T-LGLL. Since T-LGLL is a rare disease, the samples size is low. But as confirmed for each sample, hypermethylation of T-LGLL cells at various CpG sites located at enhancer regions is a hallmark of this disease. The interaction of BLC11B and C14orf64 as suggested by in silico data analysis could provide a novel pathogenetic mechanism that needs further experimental investigation.
DNA methylation is altered in T-LGLL cells compared to benign T cells. In particular, BCL11B is highly significant differentially methylated in T-LGLL cells. Although our results have to be validated in a larger patient cohort, BCL11B could be considered as a potential biomarker for this leukemia. In addition, altered gene expression and hypermethylation of enhancer regions could serve as potential mechanisms for treatment of this disease. Gene interactions of dysregulated genes, like BLC11B and C14orf64, may play an important role in pathogenic mechanisms and should be further analyzed.
T 细胞大颗粒淋巴细胞白血病(T-LGLL)是一种成熟 T 细胞白血病,通常起源于 T 细胞受体 αβ 阳性 CD8 记忆细胞毒性 T 细胞,其分子发病机制仅部分了解。DNA 甲基化在 T-LGLL 中的作用尚不清楚。我们通过基于阵列的 DNA 甲基化谱分析,比较了 11 例 T-LGLL 患者和正常对照的 T-LGLL 细胞的表观基因组图谱。为了确定驱动 T-LGLL 发病机制的分子事件,我们将 T-LGLL 病例与正常 T 细胞之间差异甲基化的基因座与 BLUEPRINT 项目良性 T 细胞的染色质分段数据进行了比较。此外,我们分析了 T-LGLL 和良性 T 细胞的基因表达数据,并在包括 5 例序贯样本在内的 17 例患者的扩展队列中通过焦磷酸测序进行了验证。
我们发现 T-LGLL 中存在与基因表达改变相关的 DNA 甲基化失调。由于 T-LGLL 是一种罕见疾病,样本量较低。但是,正如对每个样本的确认,T-LGLL 细胞中各种位于增强子区域的 CpG 位点的高甲基化是这种疾病的标志。正如计算机数据分析所建议的,BCL11B 和 C14orf64 的相互作用可能提供一种新的发病机制,需要进一步的实验研究。
与良性 T 细胞相比,T-LGLL 细胞中的 DNA 甲基化发生改变。特别是,BCL11B 在 T-LGLL 细胞中高度显著差异甲基化。尽管我们的结果需要在更大的患者队列中进行验证,但 BCL11B 可以被认为是这种白血病的潜在生物标志物。此外,增强子区域的基因表达改变和高甲基化可能作为治疗这种疾病的潜在机制。失调基因的基因相互作用,如 BCL11B 和 C14orf64,可能在发病机制中发挥重要作用,应进一步分析。